Sagent Pharmaceuticals (SGNT) Launches Oxacillin for Injection
Tweet
Share
E-mailGet Alerts SGNT Hot Sheet
Join SI Premium – FREE
Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) announced the launch of Oxacillin for Injection, USP, in three latex-free, preservative-free vial presentations. According to IMS data for the twelve-months ended May 2012, the U.S. market for Oxacillin approximated $29 million. As with all products in Sagent's portfolio, Oxacillin features the company's PreventIV MeasuresSM packaging and labeling designed to aid in the reduction of medication errors.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Nu Skin EVP of global sales takes medical leave
- loanDepot receives NYSE non-compliance notice over stock price
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
